Silverarc Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Silverarc Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-111,000	Closed	-$3.84M	–	69
2025 Q1	$3.84M	Buy	+111,000	New	+$3.74M	0.78%	32
2023 Q3	–	Sell	-50,000	Closed	-$860K	–	84
2023 Q2	$860K	Buy	50,000 +10,000	+25%	+$150K	0.27%	62
2023 Q1	$663K	Buy	+40,000	New	+$466K	0.27%	61
2022 Q1	–	Sell	-100,000	Closed	-$1.67M	–	71
2021 Q4	$1.67M	Buy	+100,000	New	+$4.23M	0.68%	44

Other funds holding BBIO

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Silverarc Capital Management's BBIO Position: Q2 2025 in Review

Silverarc Capital Management sold out of BridgeBio Pharma (BBIO) in Q2 2025, closing a stake of 111,000 shares — an estimated $3.84M sold.

Silverarc Capital Management first reported a position in BBIO in Q4 2021 and held it in 4 quarters. The position peaked at $3.84M in Q1 2025. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

Silverarc Capital Management reported no remaining BridgeBio Pharma position as of Q2 2025 after selling out during the quarter.
Silverarc Capital Management sold 111,000 BridgeBio Pharma shares in Q2 2025, an estimated $3.84M.
Silverarc Capital Management first reported a position in BridgeBio Pharma in Q4 2021 and held it in 4 quarters.
Silverarc Capital Management's BridgeBio Pharma position peaked at $3.84M in Q1 2025.
359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on Silverarc Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.